Merck & Company Inc (MRK)vsSangamo Therapeutics Inc (SGMO)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
SGMO
Sangamo Therapeutics Inc
$0.12
-10.24%
HEALTHCARE · Cap: $78.75M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 164268% more annual revenue ($65.01B vs $39.55M). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
SGMO
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Intrinsic value data unavailable for SGMO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 88.4% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -2892.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : SGMO
The strongest argument for SGMO centers on Revenue Growth. Revenue growth of 88.4% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SGMO
The primary concerns for SGMO are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while SGMO is a hypergrowth play — different risk/reward profiles.
SGMO carries more volatility with a beta of 1.50 — expect wider price swings.
SGMO is growing revenue faster at 88.4% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 30/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Sangamo Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic drugs that transform the lives of patients using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company is headquartered in Brisbane, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?